BMJ:除了下肢血管彩超,小小D二聚体也能提示深静脉血栓形成!

2022-02-19 MedSci原创 MedSci原创

使用临床试验前概率和D-二聚体相结合的诊断策略在随访期间确定了一组低风险的深静脉血栓患者,同时大大减少了对超声成像的需求。

临床评估、D-二聚体(DD2)血液检测和超声成像被广泛用于评估可疑的下肢深静脉血栓(DVT)。有证据表明,三项评估中任何两项的出现,即临床预检概率低、DD2检测阴性(<500 ng /mL)、近端静脉超声成像阴性,都与随后发生血栓性并发症的概率极低有关,可以排除深静脉血栓。

为了评价DVT诊断算法的安全性和效率,来自加拿大麦克马斯特大学医学系的专家开展了一项前瞻性诊断管理研究。将来自加拿大的大学急诊部或门诊部的有深静脉血栓症状或体征的患者进行检测,结果发表在BMJ杂志上。

该研究假设在Wells低临床预检概率和DD2<1000 ng/mL或Wells中度临床预检概率和DD2<500 ng/mL的情况下被认为可以排除DVT,而无需进一步检查。所有其他患者都有近端超声成像。重复近端超声造影仅限于最初超声造影阴性、低度或中度临床预检概率和DD2 >3000 ng/ml或高度临床预检概率和DD2>1500 ng/ml的患者。如果没有诊断出深静脉血栓,患者不接受抗凝血治疗。主要结果是三个月后出现无症状的DVT。

结果显示,1508名患者被纳入并进行了分析,其中173人(11.5%)在预定的诊断测试中患有DVT。在1275名在预定检测中没有近端DVT且没有接受抗凝治疗的患者中,有8人(0.6%,95%置信区间为0.3%至1.2%)在随访中被发现有DVT。

与传统的深静脉血栓检测策略相比,这种诊断方法将超声检查的需求从平均1.36次/病人减少到0.72次/病人(差异为-0.64,95%置信区间为-0.68至-0.60),相当于相对减少47%。

综上,使用临床试验前概率和D-二聚体相结合的诊断策略在随访期间确定了一组低风险的深静脉血栓患者,同时大大减少了对超声成像的需求。

 

参考文献:

Diagnosis of deep vein thrombosis with D-dimer adjusted to clinical probability: prospective diagnostic management study. BMJ 2022; 376 doi: https://doi.org/10.1136/bmj-2021-067378

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1698345, encodeId=58f316983455a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Dec 20 15:50:36 CST 2022, time=2022-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955581, encodeId=5fd01955581bf, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Nov 14 21:50:36 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950399, encodeId=3b8a1950399ee, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Oct 23 21:50:36 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849369, encodeId=d9dd1849369bf, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Apr 28 12:50:36 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483311, encodeId=2de21483311b1, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Feb 21 10:50:36 CST 2022, time=2022-02-21, status=1, ipAttribution=)]
    2022-12-20 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1698345, encodeId=58f316983455a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Dec 20 15:50:36 CST 2022, time=2022-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955581, encodeId=5fd01955581bf, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Nov 14 21:50:36 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950399, encodeId=3b8a1950399ee, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Oct 23 21:50:36 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849369, encodeId=d9dd1849369bf, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Apr 28 12:50:36 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483311, encodeId=2de21483311b1, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Feb 21 10:50:36 CST 2022, time=2022-02-21, status=1, ipAttribution=)]
    2022-11-14 xue8602
  3. [GetPortalCommentsPageByObjectIdResponse(id=1698345, encodeId=58f316983455a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Dec 20 15:50:36 CST 2022, time=2022-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955581, encodeId=5fd01955581bf, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Nov 14 21:50:36 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950399, encodeId=3b8a1950399ee, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Oct 23 21:50:36 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849369, encodeId=d9dd1849369bf, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Apr 28 12:50:36 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483311, encodeId=2de21483311b1, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Feb 21 10:50:36 CST 2022, time=2022-02-21, status=1, ipAttribution=)]
    2022-10-23 hxj0117
  4. [GetPortalCommentsPageByObjectIdResponse(id=1698345, encodeId=58f316983455a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Dec 20 15:50:36 CST 2022, time=2022-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955581, encodeId=5fd01955581bf, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Nov 14 21:50:36 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950399, encodeId=3b8a1950399ee, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Oct 23 21:50:36 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849369, encodeId=d9dd1849369bf, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Apr 28 12:50:36 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483311, encodeId=2de21483311b1, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Feb 21 10:50:36 CST 2022, time=2022-02-21, status=1, ipAttribution=)]
    2022-04-28 gaoxiaoe
  5. [GetPortalCommentsPageByObjectIdResponse(id=1698345, encodeId=58f316983455a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Dec 20 15:50:36 CST 2022, time=2022-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955581, encodeId=5fd01955581bf, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Nov 14 21:50:36 CST 2022, time=2022-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950399, encodeId=3b8a1950399ee, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Oct 23 21:50:36 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849369, encodeId=d9dd1849369bf, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Thu Apr 28 12:50:36 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483311, encodeId=2de21483311b1, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Mon Feb 21 10:50:36 CST 2022, time=2022-02-21, status=1, ipAttribution=)]

相关资讯

Dig Dis Sci:溃疡性结肠炎患者以及术后炎症性肠病患者出院后静脉血栓栓塞的风险均明显上升

目前我们知道,炎症性肠病 (IBD) 患者手术后住院期间内的静脉血栓栓塞 (VTE) 的风险增加是明确的,但是目前尚不清楚这种关联是否在出院后持续存在。因此,

BMJ:covid-19疫苗安全问题将如何影响疫苗信心?

认识到不确定性和安全恐惧,通过可信的信息与公众对话,以及迅速和基于科学的方案反应,继续建立和维持信任。

J Gastroenterology:日本炎症性肠病患者中动静脉血栓栓塞导致死亡的危险因素分析

炎性肠病又称炎症性肠病(IBD),为累及回肠、直肠、结肠的一种特发性肠道炎症性疾病。

Circ Cardiovasc Interv:使用自膨胀镍钛诺支架专用静脉支架可有效且安全的治疗有症状的髂股静脉阻塞——VIRTUS试验结果

慢性静脉功能不全的特点是下肢静脉回流不畅,其原因可能是深静脉血栓形成后的静脉内梗阻,也可能是外在的静脉压迫。本研究旨在确定专用静脉内支架治疗症状性髂股静脉阻塞的安全性和有效性,研究结果已在线发表于Ci

AJG:炎症性肠病患者中静脉血栓栓塞性疾病的发病率明显增高

已知,炎症性肠病 (IBD) 患者的静脉血栓栓塞 (VTE) 疾病风险会比正常人高 3 倍以上,年轻的 IBD 患者的相对风险最大

JCC: 炎症性肠病增加儿童静脉血栓栓塞的风险

炎症性肠病 (IBD) 是一种复杂的全身炎症性疾病,通常伴有肠道和肠外并发症。静脉血栓栓塞 (VTE) 是最具破坏性的肠外IBD 的并发症。

拓展阅读

BMJ:肝素治疗可降低D二聚体水平升高的中度新冠肺炎住院患者死亡风险

在中度Covid-19住院且伴有D-二聚体水平升高的患者中,接受治疗性肝素治疗可降低患者28天死亡风险,且出血风险较低

新版肺血栓栓塞症防治指南发布:D二聚体阴性,可基本除外急性肺栓塞

近日,《肺血栓栓塞症诊治与预防指南》更新。该指南在2001年指南基础上,系统评价当前包括国人在内的循证医学资料,并对临床医生关注的临床问题和结局指标进行了凝炼。

病例分享:突发胸痛,D二聚体升高,病因竟是……

患者,男,45岁,既往患有高血压病,因突发剧烈胸痛4小时前来就诊,发病后一小时在当地医院查心电图。

Ann Intern Med:ACP临床指南委员会的更佳实践建议--肺栓塞指南

新的肺栓塞指南指出过度应用CT成像和血浆D-二聚检查诊断肺栓塞,可能弊大于利。9月29号,ACP在Annals of Internal Medicine杂志上发表肺栓塞最新指南。血浆D二聚体检查可能适用于那些发生肺栓塞中等风险的患者,不适用与低风险患者。波士顿马萨诸塞州综合医院急诊科的副主任Ali S. Raja和ACP临床指南协会的同事写道:尽管评估住院,出院以及急诊患者发生肺栓塞,CT检查应用